S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Evolus Stock Forecast, Price & News

+0.09 (+0.78%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
227,889 shs
Average Volume
503,806 shs
Market Capitalization
$655.21 million
P/E Ratio
Dividend Yield
Price Target

Evolus Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.83 Rating Score
31.2% Upside
$15.33 Price Target
Short Interest
7.16% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.53mentions of Evolus in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.54 M Sold Last Quarter
Proj. Earnings Growth
From ($1.07) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.78 out of 5 stars

Medical Sector

667th out of 1,429 stocks

Pharmaceutical Preparations Industry

316th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

Evolus logo

About Evolus (NASDAQ:EOLS)

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
$-46.81 million
Pretax Margin


Sales & Book Value

Annual Sales
$99.67 million
Book Value
$1.47 per share


Free Float
Market Cap
$655.21 million

Evolus Frequently Asked Questions

Should I buy or sell Evolus stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Evolus stock.
View analyst ratings for Evolus
or view top-rated stocks.

What is Evolus' stock price forecast for 2022?

6 brokers have issued 1 year target prices for Evolus' stock. Their EOLS stock forecasts range from $10.00 to $20.00. On average, they expect Evolus' share price to reach $15.33 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price.
View analysts' price targets for Evolus
or view top-rated stocks among Wall Street analysts.

How has Evolus' stock price performed in 2022?

Evolus' stock was trading at $6.51 at the beginning of 2022. Since then, EOLS shares have increased by 79.6% and is now trading at $11.69.
View the best growth stocks for 2022 here

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Evolus

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.24. The firm earned $33.90 million during the quarter, compared to analyst estimates of $29.83 million. Evolus had a negative trailing twelve-month return on equity of 80.20% and a negative net margin of 58.28%. The company's revenue was up 177.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share.
View Evolus' earnings history

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $148.47 million.

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 44, Pay $1.23M) (LinkedIn Profile)
  • Dr. Rui Avelar C.CFP, Dip.SportMed, M.D., Chief Medical Officer and Head of R&D (Age 60, Pay $660.08k)
  • Mr. David K. Erickson, VP of Investor Relations
  • Mr. Jeffrey J. Plumer, Gen. Counsel
  • Mr. Kurt Knab, VP of Sales
  • Ms. Crystal Muilenburg, Chief Marketing Officer (Age 42)
  • Ms. Jessica Novak, Sr. VP of HR

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $11.69.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $655.21 million and generates $99.67 million in revenue each year. The company earns $-46.81 million in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for Evolus is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at [email protected].

This page (NASDAQ:EOLS) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.